PubMed Health⌕ Search

Biomedical subjects

F Devreker

Publications and source records attributed to F Devreker.

22 records · Page 2Linked to original sources
PubMed1996

Quality control in IVF with mouse bioassays: a four years' experience.

OBJECTIVE: We analyzed retrospectively the relevance of 4 years of quality control on homemade culture medium with the mouse IVF and zygote bioassay. DESIGN: In vitro or in vivo fertilized mouse oocytes were cultured in each batch of medium. Two-cell-stage and expanded blastocyst development was recorded for each batch of medium. Data on fertilization and embryo quality obtained in human in vitro fertilization were recorded for each batch. IVF treatment cycles for male infertility and cycles with sperm microinjection were excluded. RESULTS: Human oocyte fertilization dropped from 60 to 54%, respectively, from 57 to 41% in a significant way (P < 0.05 resp. P < 0.01) and the human mean embryo score decreased from 4.17 +/- 1.21 to 3.69 +/- 1.06 (P < 0.05) when media were used with a low two-cell-stage development (< or = 75%) for the mouse zygote or mouse IVF bioassay. The pregnancy rate was not affected. CONCLUSIONS: Media with high scores in mouse bioassays show higher fertilization rates and better embryo quality when used for human IVF.

Animals↗
PubMed1996

Is the subzonal-insemination procedure an efficient technique in the treatment of extreme oligoasthenoteratozoospermia?

OBJECTIVES: The present study evaluates the usefulness of the sub-zonal insemination (SUZI) for patients with previous IVF failures or affected by severe oligoasthenoteratozoospermia and the necessity of pre-treatment semen analysis. DESIGN: Twenty-five patients underwent 43 cycles of either SUZI or alternate SUZI/IVF procedures according to semen characteristics. RESULTS: Among the 571 retrieved oocytes, 398 were microinjected and 173 were treated by IVF. Among the microinjected oocytes, 19% fertilized (12% 2PN: 7% 3PN) and 96% of the 2PN oocytes developed into embryos. Thirty-one embryo transfers were performed, 8 pregnancies were obtained and 7 embryos were cryopreserved. The 2 PN rates in SUZI and IVF procedures in the same cycle were not significantly different. The analysis of the different semen samples obtained before and during the treatment reveals that the semen quality varies in such a way that the decision of the adequate microinjection strategy to follow should only be taken according to the semen quality at the day of treatment. CONCLUSION: SUZI is not a satisfactory technique for treatment neither in case of previous IVF failures nor for severe oligoasthenoteratozoospermia.

Adult↗
PubMed1996

The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate.

OBJECTIVES: To determine the efficacy and innocuousness of long-acting versus short-acting GnRH analogues (GnRH-a) in long protocol for in IVF-ET. DESIGN: Prospective randomized study. SETTING: The IVF unit at an academic hospital. PATIENTS: One hundred couples admitted for their first IVF-ET attempt. MAIN OUTCOME MEASURES: Serum concentrations of LH, E2, and P during the all cycles and duration of pituitary desensitization were assessed, as well as fertilization rate, embryo quality, and implantation and pregnancy rates. RESULTS: Significantly more days (10.8 +/- 1.8 versus 9.2 +/- 1.7 days) of stimulation and more ampules of hMG (47 +/- 22 versus 33 +/- 16) were necessary to obtain similar numbers of embryos of quality with the long-acting GnRH-a. Implantation and delivery rates were significantly lower with the long-acting GnRH-a (32.8% versus 21.1%; 48.9% versus 29.1%, respectively). CONCLUSIONS: As the long-acting GnRH-a might interfere with the luteal phase and embryo development, short-acting GnRH-a should be preferred for ovarian hyperstimulation in IVF-ET.

Adult↗